Branched short-chain fatty acids modulate glucose and lipid metabolism in primary adipocytes

Emilia Heimanna, Margareta Nymanb, Ann-Ki Pålbrinkc, Karin Lindkvist-Peterssonc, and Eva Degermana

aDepartment of Experimental Medical Science, Section for Diabetes, Metabolism and Endocrinology, Lund University, Lund, Sweden; bFood for Health Science Center, Lund University, Lund, Sweden; cDepartment of Experimental Medical Science, Section for Medical Structural Biology, Lund University, Lund, Sweden

ABSTRACT
Short-chain fatty acids (SCFAs), e.g. acetic acid, propionic acid and butyric acid, generated through colonic fermentation of dietary fibers, have been shown to reach the systemic circulation at micromolar concentrations. Moreover, SCFAs have been confered anti-obesity properties in both animal models and human subjects. Branched SCFAs (BSCFAs), e.g., isobutyric and isovaleric acid, are generated by fermentation of branched amino acids, generated from undigested protein reaching colon. However, BSCFAs have been sparsely investigated when referring to effects on energy metabolism. Here we primarily investigate the effects of isobutyric acid and isovaleric acid on glucose and lipid metabolism in primary rat and human adipocytes. BSCFAs inhibited both cAMP-mediated lipolysis and insulin-stimulated de novo lipogenesis at 10 mM, whereas isobutyric acid potentiated insulin-stimulated glucose uptake by all concentrations (1, 3 and 10 mM) in rat adipocytes. For human adipocytes, only SCFAs inhibited lipolysis at 10 mM. In both in vitro models, BSCFAs and SCFAs reduced phosphorylation of hormone sensitive lipase, a rate limiting enzyme in lipolysis. In addition, BSCFAs and SCFAs, in contrast to insulin, inhibited lipolysis in the presence of wortmannin, a phosphatidylinositide 3-kinase inhibitor and OPC3911, a phosphodiesterase 3 inhibitor in rat adipocytes. Furthermore, BSCFAs and SCFAs reduced insulin-mediated phosphorylation of protein kinase B. To conclude, BSCFAs have effects on adipocyte lipid and glucose metabolism that can contribute to improved insulin sensitivity in individuals with disturbed metabolism.

Introduction
A diet rich in dietary fibers influences the regulation of weight and appetite control as well as energy homeostasis.1-3 These effects are most likely mediated by the short-chain fatty acids (SCFAs), generated through colonic fermentation of dietary fibers.4-11 The most abundant SCFAs, namely acetic acid, propionic acid and butyric acid, appear to have anti-obesity properties in both animal models and human subjects when orally distributed.12-21 For example, a high fat diet supplemented with acetic acid, propionic acid or butyric acid improved both insulin sensitivity and protected against weight gain in animal models.18,19 Furthermore, inulin-propionate, a dietary fiber combined with the ester of propionic acid, reduced energy intake, accumulation of intra-abdominal adiposity and lipid content in the liver in obese human individuals.20

Branched SCFAs (BSCFAs), e.g. isobutyric and isovaleric acid, are generated by fermentation of branched amino acids, valine, leucine and isoleucine,22 generated from undigestible protein reaching colon.23,24 However, an increase of isobutyric acid has also been demonstrated after ingestion of certain dietary fibers, such as polydextrose.25 To the best of our knowledge, less is known regarding the role of gut-derived BSCFAs in the regulation of metabolism. Nevertheless, a recent study showed that a diet composed of brown beans increased colonic production of isobutyric acid and propionic acid, which was associated with lowered glucose and insulin concentrations in the blood as well as increased production of the satiety hormone pancreatic peptide YY (PYY).26 Furthermore, by supplementing the drinking water with leucine, a branched amino acid, to mice fed a high-fat diet has been shown to improve glucose tolerance and insulin signaling as well as decrease inflammation in adipose tissue.27 In obesity, adipose tissue shows a number of structural, morphological and functional alterations associated with a deteriorated fat storage capacity, an imbalance in the circulating levels of fatty acids and adipose tissue-derived hormones as well as pro-inflammatory cytokines that promote insulin resistance.28-31 Thus,
Adipose tissue is a key target tissue for prevention of type 2 diabetes. We and others have previously demonstrated health beneficial effects of SCFAs on adipocyte function, involving effects on lipolysis, lipogenesis and glucose uptake. BSCFAs have not been associated with outcomes on host health as is the case for SCFAs and specifically, effects of BSCFAs have not been reported when referring to effects on adipocyte metabolism. In the current study, we investigate whether the 2 BSCFAs isobutyric acid and isovaleric acid have the ability to modulate adipocyte function.

Results

**Branched short-chain fatty acids inhibit isoproterenol-stimulated lipolysis in a PI3-kinase and PDE3 independent manner**

Adipocyte lipolysis is mediated by hormones that increase cAMP, leading to protein kinase A (PKA)-mediated phosphorylation and activation of hormone sensitive lipase (HSL), a rate limiting enzyme in hormone-stimulated lipolysis. The effects of the BSCFAs isobutyric acid and isovaleric acid, and the SCFA acetic acid on basal and isoproterenol-stimulated lipolysis were investigated in primary rat adipocytes. As shown in Table 1, BSCFAs and acetic acid inhibited isoproterenol-stimulated lipolysis, which was associated with reduced phosphorylation of HSL (Fig. 1, Table 2).

**Table 1.** BSCFAs and acetic acid inhibit lipolysis in rat adipocytes. Lipolysis was measured after 30 minutes of stimulation without (BASAL) or with 30 nM isoproterenol (ISO) in the absence (CTRL) or presence of isobutyric acid (I-BA), isovaleric acid (I-VA) and acetic acid (AA). The values for I-BA, I-VA or AA are related to respective CTRL (set to 1) in BASAL and ISO condition. The mean ± SD (n = 3-5) were used and significance levels were accepted when **p < 0.05, *p < 0.01 and ***p < 0.001. a8.4-fold, b8.3-fold, c6.4-fold increase in ISO-stimulated lipolysis compared to BASAL.

|       | 1 I-BA | 3 I-BA | 10 I-BA |
|-------|--------|--------|---------|
| BASAL |        |        |         |
| ISO   | 0.74   | 0.90   | 0.52    |
|       | 0.31   | 0.26   |         |
|       |        |        |         |
|       |        |        |         |
| BASAL |        |        |         |
| ISO   | 1.07   | 0.98   | 0.12    |
|       | 0.39   | 0.05   |         |
|       |        |        |         |
| BASAL |        |        |         |
| ISO   | 1.40   | 1.05   | 0.21    |
|       | 0.33   | 0.08   |         |
|       |        |        |         |

**Figure 1.** BSCFAs and SCFAs inhibit ISO-potentiated phosphorylation of HSL in primary rat and human adipocytes. In A-B, rat adipocytes were stimulated without (Ctrl) and with isoproterenol (ISO) in the presence or absence of 3 and 10 mM isobutyric acid (I-BA), isovaleric acid (I-VA), propionic acid (PA) and butyric acid (BA) for 10 minutes (n = 3). In C, human adipocytes were stimulated with ISO in the presence or absence of 10 mM I-BA or I-VA for 10 minutes (n = 3). Homogenates were subjected to immunoblot analysis and membranes were probed with antibodies against pHSLS563 and β-actin. Representative blots are shown.

Insulin mediates its antilipolytic effect to a large extent via a phosphatidylinositol 3-kinase (PI3 kinase)- and protein kinase B (PKB)-dependent activation of the cAMP-degrading enzyme phosphodiesterase (PDE) 3B. However, as shown in Figure 2, the PI3 kinase-selective inhibitor wortmannin and the PDE3-selective inhibitor OPC3911 did not prevent the antilipolytic effect of either branched or non-branched SCFAs on isoproterenol-mediated lipolysis, whereas the antilipolytic effect of insulin was blocked by the inhibitors. To get the human perspective, we also studied lipolysis in adipocytes isolated from subcutaneous adipose tissue of human donors. BSCFAs and SCFAs reduce phosphorylation of HSL whereas significant inhibition of lipolysis was obtained with SCFAs (Fig. 1, Fig. 3, Table 2).

**Branched short-chain fatty acids inhibit basal and stimulated lipogenesis**

The effect of BSCFAs and acetic acid on lipogenesis was studied in primary rat adipocytes. Both basal and insulin-stimulated lipogenesis, measured as the incorporation of [3H]-labeled glucose into cellular lipids, were inhibited by isobutyric and isovaleric acid, although to a lesser extent for isovaleric acid in the basal condition (Table 3). Also, acetic acid resulted in inhibition of lipogenesis (Table 3).
**Isobutyric acid potentiates insulin-stimulated glucose uptake**

The effect BSCFAs as well as acetic acid on glucose uptake was studied in primary rat adipocytes. As shown in Table 4, isobutyric acid induced a small, but significant potentiation of both basal and insulin-stimulated glucose uptake. The highest concentration of isovaleric acid inhibited basal glucose uptake, while no effect on insulin-stimulated glucose uptake was observed, which was also the case for acetic acid.

**BSCFAs and SCFAs inhibit insulin-induced phosphorylation of protein kinase B**

To elucidate whether BSCFAs and SCFAs mediate their effect via PKB, a kinase involved in most acute insulin-mediated metabolic responses, we investigated their action.
effect on PKB phosphorylation. The two regulatory sites, Thr308 and Ser473 in PKBα, are phosphorylated by PDK1 and the TORC2 complex, respectively, and are necessary for full activation of the kinase.41 Figure 4 and Table 5 depict that insulin-mediated phosphorylation of PKB at Thr308 and Ser473 was decreased in response to BSCFAs and SCFAs in rat and human adipocytes.

Materials and methods

Animal model

Sprague Dawley male rats, 36-41 d of age, purchased from Charles River Laboratories (Germany), were kept under standardized conditions in the animal house facilities at Lund University. The Committee of ethical animal research in Malmö and Lund has approved all experimental procedures (permission number: M245-12).

Table 3. BSCFAs and acetic acid inhibit lipogenesis in primary rat adipocytes. Lipogenesis was measured after 30 minutes of stimulation without (BASAL) or with 1 nM insulin (INS) in the absence (CTRL) or presence of 1, 3 and 10 mM isobutyric acid (I-BA), isovaleric acid (I-VA) or acetic acid (AA). The values for I-BA, I-VA and acetic acid are related to respective CTRL (set to 1), either in a basal or an insulin-stimulated state. Mean ± SD (n = 3-4) were used and significance levels were accepted when "p < 0.05, "p < 0.01 and ""p < 0.001. 412-fold, 6.4-fold, 5.7-fold increase in insulin-stimulated lipogenesis compared to BASAL.

|         | 1 I-BA | 3 I-BA | 10 I-BA |
|---------|--------|--------|---------|
| BASAL   | Mean Mean SD Mean Mean SD Mean Mean SD |
| ISO 1a  | 0.90 0.23 0.90** 0.23 0.38*** 0.12 |
| ISO 1b  | 0.98 0.09 0.88 0.14 0.61** 0.3 |

Table 4. Isobutyric acid potentiates insulin-stimulated glucose uptake in primary rat adipocytes. Glucose uptake was measured after 30 minutes of stimulation without (BASAL) or with 1 nM insulin (INS) in the absence (CTRL) or presence of 1, 3 and 10 mM isobutyric acid (I-BA), isovaleric acid (I-VA) and acetic acid (AA). The values for I-BA, I-VA or AA are related to respective CTRL (set to 1), either in a basal or an insulin-stimulated state. Mean ± SD (n = 6-7) were used and significance levels were accepted when "p < 0.05, "p < 0.01 and ""p < 0.001. 2.9-fold, 2.8-fold, 2.1-fold increase in insulin-stimulated glucose uptake compared to BASAL.

|         | 1 I-BA | 3 I-BA | 10 I-BA |
|---------|--------|--------|---------|
| BASAL   | Mean Mean SD Mean Mean SD Mean Mean SD |
| INS 1a  | 1.29 0.19 1.3** 0.18 1.24** 0.21 |
| INS 1b  | 1.24*** 0.05 1.27*** 0.1 1.25*** 0.11 |
| INS 1c  | 0.94 0.12 0.95 0.05 0.69** 0.1 |
| INS 1d  | 1.02 0.03 0.74 0.2 1.01 0.12 |
| INS 1e  | 0.98 0.09 0.87 0.14 0.82** 0.1 |
| INS 1f  | 0.98 0.06 1.06 0.11 1.14 0.21 |
Human adipose tissue

Patients with scheduled reconstructive breast surgery, recruited by the surgeons at Skane University Hospital, Sweden, were included in the study. Adipose tissue, removed from the abdominal subcutaneous region of the patients, reached the laboratory within one hour after surgery. The preparation of adipocytes was immediately initiated and usually 3 g of subcutaneous adipose tissue was used for an experiment. All experiments were approved by the Regional Ethics Committee in Lund, Sweden (Dnr 2013/298).

Adipocyte isolation

Epididymal white adipose tissue was isolated and digested in collagenase (Sigma Aldrich/C6885) for 30 minutes at 37°C with agitation and then washed as previously described. The total volume of packed cells (lipocrit) in the adipocyte suspension was determined as described by Fine et al. (2007). The adipocytes were resuspended and diluted to the final cell concentration (1-10%), depending on experimental setup.

Lipolysis

Lipolysis was measured as described by Dole et al. (2007). Aliquots (400 μl) of 5% (rat) or 10% (human) suspensions of adipocytes were prepared in Krebs Ringers HEPES (KRH) containing 25 mM HEPES (pH 7.4),...
120 mM NaCl, 4.7 mM KCl, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 2.5 mM CaCl₂, 1% BSA, 2 mM glucose, and 200 nM adenosine and incubated with or without 30 nM DL-Isoproterenol hydrochloride (ISO) (Sigma-Aldrich, St. Louis, MO, USA) in the presence or absence of 1, 3 and 10 mM isobutyric acid (Sigma-Aldrich), isovaleric acid (Merck, Kenilworth, NJ, USA) or acetic acid (Merck) at 37°C for 30 minutes in a shaking device (150 rpm). The cell-free medium was transferred to wells and buffer containing 50 mM glycine, 0.05% hydrazine-hydrate, 1 mM MgCl₂, 0.75 mg/ml ATP (Sigma-Aldrich), 0.375 mg/ml NAD (Roche, Pleasanton, CA, USA), 25 μg/ml glycerol-3-phosphate dehydrogenase (Roche) and 0.5 μg/ml glycerol kinase (Roche) was added. Lipolysis was measured at optical density of 340 as the release of glycerol into the cell-free medium.

De novo lipogenesis from radio labeled glucose

Lipogenesis was measured as described by Moody et al. Aliquots (700μl) of a 2% suspension of adipocytes were prepared in KRH with low glucose (containing 0.55 mM glucose and 3.5% BSA without adenosine) and 14 μl D-[6-³H (N)] glucose (22 μCi/ml) 0.81 Bq/ml (Perkin Elmer, Waltham, MA, USA) was added as substrate for lipogenesis. Cells were stimulated with 1 nM insulin (Novonordisk, Bagsvaerd, Denmark) in the presence or absence of 1, 3 and 10 mM isobutyric acid, isovaleric acid, acetic acid or propionic and butyric acid. Cells were homogenized with a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 1mM EGTA, 1 mM EDTA, 1% NP40, 1 mM Na- orthovanadate, 50 mM NaF, 5 mM Na-pyrophosphate, 0.27 M sucrose, Nonidet P 40 (Sigma-Aldrich) and Complete Protease Inhibitor (containing inhibitors for serine-, cysteine-, and metalloproteases as well as calpains) (Roche) and centrifuged at 13 600 x g for 15 minutes. The total protein amount was determined according to Bradford. Samples (15-30 μg) were supplemented with NuPAGE sample reducing agent (Novex, Grand Island, NY, USA) and subjected to SDS-PAGE. Proteins were electrotransferred to Amerham Hybond-C Extra nitrocellulose membranes (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and the membranes were stained with Ponceau S (0.1% in 5% acetic acid) and then blocked with 10% milk in a buffer, consisting of 20 mM Tris-HCl, pH 7.6, 137 mM NaCl and 0.1% (v/w) Tween-20 for 60 min. Membranes with proteins were probed with antibodies for protein kinase B (PKB) (Cell Signaling Technology Inc., Danvers, MA, USA), phospho-PKB (S473) (Cell Signaling) and phosho-PKB (T308) (Cell Signaling), phospho-HSL (S563) (Cell Signaling) and β-actin (Sigma Aldrich) and incubated overnight at 4°C. Proteins were detected using the chemiluminescent Super Signal West Pico Luminol/Enhancer solution (Thermo Fisher Scientific, Waltham, MA, USA) and the ChemiDoc XRS+ Imager (Bio-Rad Laboratories, Hercules, CA, USA.). Image Lab Software (Bio-Rad Laboratories) was used for quantification.

Statistics

Data are presented as mean ± SD from the indicated number of experiments. Statistically significant differences were analyzed using Student’s t-test and significance levels were accepted when *p < 0.05, **p < 0.01 and ***p < 0.001.

Discussion

The ability of colon-produced SCFAs and BSCFAs to act upon peripheral tissues like adipose tissue requires that a
fraction of these molecules reaches the systemic circulation. Beyond the liver, the concentration of all 3 SCFAs (acetic acid > propionic acid > butyric acid) as well as isobutyric acid have been estimated to be in the micromolar range in the systemic circulation. Furthermore, using stable isotope technology, systemic availability of colonic-administered acetate, propionate and butyrate was shown to be 36%, 9% and 2%, respectively. In another study, a net uptake of the SCFAs by adipose tissue, measured as the arteriovenous difference across the tissue times the tissue could be demonstrated. In summary, SCFAs and BSCFAs are available in the systemic circulation albeit at lower concentration than used in the current study having isolated primary adipocytes as in vitro model.

The mechanisms whereby BSCFAs and SCFAs mediate their effects observed on biological responses and cellular signaling that have been reported herein, are still unclear. However, it has become increasingly evident that all macronutrients, carbohydrates, proteins and lipids, also play an important role in the regulation of energy metabolism as signaling molecules. Moreover, free fatty acid receptors (FFARs) are likely to play important roles in fatty acid mediated regulation of energy metabolism. Specifically, FFAR2 and 3 have been linked to a number of effects exerted by SCFAs in adipocytes, for example, FFAR2 was shown to suppress lipolysis and stimulate adipogenesis as well as adipocyte differentiation whereas FFAR3 was shown to induce leptin expression. With regards to BSCFAs and their binding to FFARs, to our knowledge, less is known. In addition to acting as signaling molecules, BSCFAs and SCFAs could mediate metabolic effects in adipocytes by entering various metabolic routes as discussed below.

The finding that isobutyric and isovaleric acid inhibited isoproterenol-mediated lipolysis and decreased isoproterenol-induced phosphorylation of HSL, indicate a role for BSCFAs in the regulation of energy homeostasis by protecting against lipotoxicity, as has previously been reported for SCFAs. Importantly, the mechanism behind the anti-lipolytic effect of BSCFAs and SCFAs appears not to involve components utilized by insulin to mediate inhibition of lipolysis. Namely, BSCFAs and SCFAs induced inhibition of lipolysis in the presence of inhibitors for PI3 kinase and PDE3B, whereas the anti-lipolytic effect of insulin was inhibited as expected under those conditions. Furthermore, phosphorylation of PKB, a key kinase in mediating acute metabolic effects of insulin such as inhibition of lipolysis, was downregulated both at Ser473 and Thr308, 2 activity controlling phosphorylation sites. Having that in mind, it will be interesting to test the ability of BSCFAs and SCFAs to inhibit lipolysis in insulin-resistant adipocytes isolated from obese individuals. Obese adipose tissue often has dysregulated lipolysis, leading to excessive release of fatty acids and decreased insulin sensitivity. As shown in this paper, both BSCFAs and SCFAs reduce phosphorylation of HSL whereas significant inhibition of lipolysis was only obtained with SCFAs.

The finding that BSCFAs decrease the rate of de novo lipogenesis, measured as the incorporation of [3H]-labeled glucose into cellular lipids, is in agreement with previous results with non-branched SCFAs. Altogether, these findings indicate that BSCFAs and SCFAs facilitate storage of diet-derived lipids in adipocytes rather than performing de novo synthesis, which at least under conditions of fat overconsumption appears metabolically beneficial. Also, the effect to diminish de novo lipogenesis might lead to an increased β-oxidation due to reduced level of malonyl CoA, a metabolite known to inhibit the transport of fatty acids into the mitochondria. The inhibitory effect on PKB phosphorylation observed in response to the branched and non-branched SCFAs and the phosphorylation and inactivation of ACC might be molecular mechanisms for diminished de novo lipogenesis. Isovaleric acid-containing porpoise oil, given in the diet, has ameliorating effects on fatty liver in OLETF (Otsuka Long-Evans Tokushima Fatty) rat, a model for type 2 diabetes, by increasing serum levels of adiponectin and enhancing lipoprotein synthesis and secretion. However, isobutyric and isovaleric acid have been scarcely investigated with regard to effects on de novo lipogenesis.

The finding that isobutyric acid significantly increased both basal and insulin-stimulated glucose uptake is in agreement with recently obtained results for propionic acid and to some extent also for butyric acid in rodent primary and differentiated adipocytes. Phosphorylation of PKB is one key event in insulin-induced glucose uptake, however, phosphorylation of PKB was shown to be downregulated by both branched and non-branched SCFAs. In agreement with our findings on PKB, Kimura et al have observed a decreased insulin-mediated phosphorylation of PKB at Ser473 in response to acetic acid in adipocytes, an effect that was mediated by GPR43.

In addition to acting as signaling molecules, BSCFAs and SCFAs could act as energy substrates in adipocytes by entering routes in lipid and carbohydrate metabolism as has been described in colonocytes and hepatocytes. In hepatocytes, acetate and butyrate have been described to be mostly introduced into lipid biosynthesis, whereas propionate will mainly be incorporated into gluconeogenesis. With regards to adipocytes, BSCFAs and SCFAs might enter the lipogenic route after uptake and activation by short chain CoA synthases. Thus, the inhibitory effect we observe on de novo lipogenesis from glucose could, at least to some extent, be explained by the ability of BSCFAs/SCFAs to generate
“competing” non-labeled acetyl-CoAs for the synthesis of fatty acids. Likewise, it is possible that SCFAs and BSCFAs, by the generation of long chain acyl-CoAs, inhibit lipolysis by the inhibition of ATGL (triglyceride lipase) and/or HSL.61-63

To summarize, in the current investigation we have observed a number of effects in response to BSCFAs and SCFAs on lipid and glucose metabolism and signaling in adipocytes, possible mediated by FFAR 2 and 3. However, the possibility that the effects observed are mediated by BSCFAs and SCFAs acting as substrates by entering various routes in lipid and carbohydrate metabolism in adipocytes should not be excluded.

Abbreviations

SCFA short-chain fatty acid
BSCFA branched short-chain fatty acids
BA butyric acid
PA propionic acid
I-BA isobutyric acid
I-VA isovaleric acid
PDE3B phosphodiesterase 3B
HSL hormone sensitive lipase
PKB protein kinase B
PI3 kinase phosphatidylinositol 3-kinase

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

Eva Ohlson is acknowledged for excellent technical assistance. Dr. Jens Martin Larsson, Britt-Louise Boman, Maria Borg Jönsson, Dr. Henny Svensson and Dr. Carolin Freccero and co-workers at the Department of Plastic and Reconstructive Surgery in Malmö in Sweden are all gratefully acknowledged for the delivery of human adipose tissue.

Funding

The study was financially supported by the Antidiabetic Food Center (AFC), a VINNOVA VINN Excellence Center at Lund University, Royal Physiographic Society in Lund, the Swedish Society of Medicine and the Albert Pahlsson Foundation.

Author contributions

All authors contributed to the design of the study and manuscript writing. EH contributed to the conduct of the study and data collection, whereas all authors contributed with analysis as well as data interpretation.

References

[1] Brownell AM, Caers W, Gibson GR, Kendall CW, Lewis KD, Ringel Y, Slavin JL. Prebiotics and the health benefits of fiber: current regulatory status, future research, and goals. J Nutr 2012; 142(5):962-74.
[2] Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34 (1):39-58; PMID:23159341; http://dx.doi.org/10.1016/j.ynam.2012.11.001
[3] Galisteo M, Duarte J, Zarzuelo A. Effects of dietary fibers on disturbances clustered in the metabolic syndrome. J Nutr Biochem 2008; 19(2):71-84; PMID:17618108; http://dx.doi.org/10.1016/j.jnutbio.2007.02.009
[4] Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016; 7(3):189-200.
[5] Votina A, Blaut M. The intestinal microbiota in metabolic disease. Nutrients 2016; 8(4):202; http://dx.doi.org/10.3390/nu8040202
[6] Rios-Covian D, Ruas-Madiedo P, Margolles A, Guimonde M, de Los Reyes-Gavilan CG, Salazar N1. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol 2016;7:185.
[7] Utschneider KM, Kratz M, Damman CJ, Hullarg M. Mechanisms linking the Gut microbiome and glucose metabolism. J Clin Endocrinol Metab 2016; 101(4):1445-54; PMID:26938201
[8] Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 2015; 11(10):577-91; PMID:26260141; http://dx.doi.org/10.1038/nrendo.2015.128
[9] den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The roleof short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. JLipid Res 2013; 54 (9):2325-40; PMID:23821742; http://dx.doi.org/10.1194/jlr.R036012
[10] Layden BT, Angueira AR, Brodsky M, Durai V, Lowe WL Jr. Short chain fatty acids and their receptors: new metabolic targets. Transl Res 2013; 161(3):131-40; PMID:23146568; http://dx.doi.org/10.1016/j.trsl.2012.10.007
[11] Nyangale EP, Mottram DS, Gibson GR. Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res 2012; 11 (12):5573-85; http://dx.doi.org/10.1021/pr300637d
[12] Boillot J, Alamowitch C, Berger AM, Luo J, Bruzzo F, Bornet FR. Effects of dietary propionate on hepatic glucose production, whole-body glucose utilization, carbohydrate and lipid metabolism in normal rats. Br J Nutr 1995; 73(2):241-51
[13] Berggren AM, Nyman EM, Lundquist I, Bjorck IM. Influence of orally and rectally administered propionate on cholesterol and glucose metabolism in obese rats. Br J Nutr 1996; 76(2):287-94.
[14] Todesco T, Rao AV, Bosello O, Jenkins DJ. Propionate lowers blood glucose and alters lipid metabolism in healthy subjects. Am J Clin Nutr 1991; 54(5):860-5.
[15] Wolever TM, Spaadofa P, Eshuis H. Interaction between colonic acetate and propionate in humans. Am J Clin Nutr 1991; 53(3):681-7.
[16] Chen WJ, Anderson JW, Jennings D. Propionate may mediate the hypocholesterolemic effects of certain soluble plant fibers in cholesterol-fed rats. Proc Soc Exp Biol Med 1984; 175(2):215-8; http://dx.doi.org/10.3181/00379727-175-41791

[17] Laurent C, Simonneau C, Marks L, Brasci S, Champ M, Charbonnel B, Krempf M. Effect of acetate and propionoate on fasting hepatic glucose production in humans. Eur J Clin Nutr 1995; 49(7):484-91.

[18] Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevere M, Cefalu WT, Ye J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58(7):1509-17.

[19] Lin HV, Frassetto A, Kowalki Ej, Jr., Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012; 7(4):e35240

[20] Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zae-Varghese SE, MacDougall K, Preston T, Telford C, Finlayson GS, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 2015; 64(11):1744-54.

[21] Al-Lahham S, Roelofsen H, Rezaee F, Weening D, Hoek A, Vonk R, Venema K. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur J Clin Invest 2012; 42(4):357-64.

[22] Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 2014; 10(12):723-36.

[23] Yao CK, Muir JG, Gibson PR. Review article: insights into colonic protein fermentation, its modulation and potential health implications. Aliment Pharmacol Ther 2016; 43(2):181-96.

[24] Zabberger JM, Arch JR, Green A. Butyrate and other short-chain fatty acids increase the rate of lipolysis in 3T3-L1 adipocytes. PeerJ 2014; 2:e61; http://dx.doi.org/10.7717/peerj.611

[25] Heimann E, Nyman M, Degerman E. Propionic acid and butyric acid inhibit lipolysis and de novo lipogenesis and increase insulin-stimulated glucose uptake in primary rat adipocytes. Adipocyte 2015; 4(2):81-8; PMID:26167409; http://dx.doi.org/10.4161/1623945.2014.960694

[26] Hong YH, Nishimura Y, Hishikawa D, Tszuki H, Miyahara H, Gotoh C, Choi KC, Feng DD, Chen C, Lee HG, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPR43. Endocrinology 2005; 146(12):5092-9; PMID:16123168; http://dx.doi.org/10.1210/en.2005-0545

[27] Ge H, Li X, Weizsmann J, Wang P, Baribault H, Chen JL, et al. Activation of G protein- coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008; 149(9):4519-26; PMID:18499755; http://dx.doi.org/10.1210/en.2008-0059

[28] Zaibi MS, Stocker CJ, O’Dowd J, Davies A, Bellahcene M, Cawthorne MA, Brown AJ, Smith DM, Arch JR. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 2010; 584(11):2381-6; PMID:20399779; http://dx.doi.org/10.1016/j.febslet.2010.04.027

[29] Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashiwara D, Hirano K, Tan T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013; 4:1829; PMID:23652017; http://dx.doi.org/10.1038/ncomms2852

[30] Aberdein N, Schweizer M, Ball D. Sodium acetate decreases phosphorylation of hormone sensitive lipase in isoproterenol-stimulated 3T3-L1 mature adipocytes. Adipocyte 2014; 3(2):121-5; PMID:24719785; http://dx.doi.org/10.4161/adip.27936

[31] Lafontan M. Advances adipose tissue metabolism. Int J Obes(Lond) 2008; 32(Suppl 07):S39-51.

[32] Rumberger JM, Arch JR, Green A. Butyrate and other short-chain fatty acids increase the rate of lipolysis in 3T3-L1 adipocytes. PeerJ 2014; 2:e61; http://dx.doi.org/10.7717/peerj.611

[33] Honnor RC, Dhillon GS, Londos C. cAMP-dependent protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation, and predictability in behavior. J Biol Chem 1985; 260(28):15122-9; PMID:19158325; http://dx.doi.org/10.1152/jbc.19158325

[34] Berggreen C, Gormand A, Omar B, Degerman E, Goransson AB, Sjostrom L, Manganiello V. From PDE3B to the regulation of energy homeostasis. Curr Opin Pharmacol 2011; 11(6):676-82; PMID:22001403; http://dx.doi.org/10.1016/j.coph.2011.09.015

[35] Toker A, Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul 2014; 55:28-38.

[36] Honnor RC, Dhillon GS, Londos C. cAMP-dependent protein kinase and lipolysis in rat adipocytes. II. Cell preparation, manipulation, and predictability in behavior. J Biol Chem 1985; 260(28):15122-9; PMID:19158325

[37] Fine JB, DiGirolamo M. A simple method to predict cellular density in adipocyte metabolic incubations. Int J Obes Relat Metab Disord 1997; 21(9):764-8; PMID:9376888; http://dx.doi.org/10.1038/sj.ijo.0800469
[44] Dole VP, Meinertz H. Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem 1960; 235:2595-9; PMID:13817286

[45] Moody AJ, Stan MA, Stan M, Gliemann J. A simple free fat-cell bioassay for insulin. Horm Metab Res 1974; 6(1):12-6.

[46] Foley JE, Kashiwagi A, Verso MA, Reaven G, Andrews J. Improvement in in vitro insulin action after one month of insulin therapy in obese noninsulin-dependent diabetics. Measurements of glucose transport and metabolism, insulin binding, and lipolysis in isolated adipocytes. J Clin Invest 1983; 72(6):1901-9; PMID:6358258; http://dx.doi.org/10.1172/JCI111153

[47] Cummings JH, Pomare EW, Branch WJ, Cummings JH. Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest 1985; 75(5):1448-54; PMID:3998144; http://dx.doi.org/10.1172/JCI111847

[48] Peters SG, Pomare EW, Fisher CA. Portal and peripheral blood short chain fatty acid concentrations after caecal lactulose instillation at surgery. Gut 1992; 33(9):1249-52; http://dx.doi.org/10.1136/gut.33.9.1249

[49] Pomare EW, Branch WJ, Cummings JH. Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest 1985; 75(5):1448-54; PMID:3998144; http://dx.doi.org/10.1172/JCI111153

[50] Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN. Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr 2005; 82(3):559-67; PMID:16155268

[51] Boets E, Gomand SV, Deroover L, Preston T, Vermeulen T, Kedzierski RM, Yanagisawa M. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A 2004; 101(4):1045-50; PMID:14722361; http://dx.doi.org/10.1073/pnas.2637002100

[52] Czech MP, Tencerova M, Pedersen DJ, Aouadi M. Insulin signalling mechanisms for triacylglycerol storage. Diabetologia 2013; 56(5):949-64; PMID:23443243; http://dx.doi.org/10.1007/s00125-013-2869-1

[53] Schreurs M, Kuipers F, van der Leij FR. Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev 2010; 11:380-8; PMID:19694967; http://dx.doi.org/10.1111/j.1467-789X.2009.00642.x

[54] Shirouchi B, Nagao K, Furuya K, Nagai T, Ichikura K, Tokairin S, et al. Physiological functions of iso-type short-chain fatty acid and omega 3 polyunsaturated fatty acids containing oil in obese OLETF rats. J Oleo Sci 2010;59(6):299-305; PMID:20484835

[55] Astbury SM, Corfe BM. Uptake and metabolism of the short-chain fatty acid butyrate, a critical review of the literature. Curr Drug Metab 2012; 13(6):815-21; PMID:22571479; http://dx.doi.org/10.2174/138920012800840428

[56] Grevengood TJ, Klett EL, Coleman RA. Acyl-CoA metabolism and partitioning. Annu Rev Nutr 2014; 34:1-30; PMID:24819326; http://dx.doi.org/10.1146/annurev-nutr-071813-105541

[57] Garrido-Sánchez L, García-Fuentes E, Fernández-García D, Escote X, Alcaide J, Perez-Martinez P, Vendrell J, Tinhonhes FJ. Zinc-Alpha 2-glycoprotein gene expression in adipose tissue is related with insulin resistance and lipolytic genes in morbidly obese patients. PLoS One 2012; 7(3):e33264; PMID:22442679; http://dx.doi.org/10.1371/journal.pone.0033264

[58] Nakamura Y, Sato T, Shimmura Y, Miura Y, Kojima M. Fabp3 and brown adipocyte-characteristic mitochondrial fatty acid oxidation enzymes are induced in beige cells in a different pathway from UCP1. Biochem Biophys Res Commun 2013; 441(1):42-6; PMID:24129192; http://dx.doi.org/10.1016/j.bbrc.2013.10.014

[59] Smith AJ, Thompson BR, Sanders MA, Bernlohr DA. Interaction of the adipocyte fatty acid-binding protein with the hormone-sensitive lipase: regulation by fatty acids and phosphorylation. J Biol Chem 2003; 278(44):32424-32; PMID:12350574; http://dx.doi.org/10.1074/jbc.M300495200

[60] Bosch JL, Bousquet-Melou M, Le Duigou F. Uptake and catabolism of long-chain fatty acids in isolated adipocytes. J Biol Chem 2010; 285(25):19235-43; PMID:20376271; http://dx.doi.org/10.1074/jbc.M110.191044